These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19114852)

  • 21. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
    Clumeck N; Cahn P; Molina JM; Mills A; Nijs S; Vingerhoets J; Witek J
    Int J STD AIDS; 2010 Nov; 21(11):738-40. PubMed ID: 21187353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etravirine: new drug. Multidrug-resistant HIV: another option.
    Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers.
    Peeters M; Janssen K; Kakuda TN; Schöller-Gyüre M; Lachaert R; Hoetelmans RM; Woodfall B; De Smedt G
    Ann Pharmacother; 2008 Jun; 42(6):757-65. PubMed ID: 18445705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
    Vingerhoets J; Tambuyzer L; Azijn H; Hoogstoel A; Nijs S; Peeters M; de Béthune MP; De Smedt G; Woodfall B; Picchio G
    AIDS; 2010 Feb; 24(4):503-14. PubMed ID: 20051805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
    Johnson LB; Saravolatz LD
    Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etravirine(Intelence) for HIV infection.
    Med Lett Drugs Ther; 2008 Jun; 50(1288):47-8. PubMed ID: 18551091
    [No Abstract]   [Full Text] [Related]  

  • 28. Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.
    Hill A; Grossman H; Cohen C; Nadler J; Peeters M
    HIV Clin Trials; 2007; 8(2):68-76. PubMed ID: 17507322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.
    Towner WJ; Cassetti I; Domingo P; Nijs S; Kakuda TN; Vingerhoets J; Woodfall B
    Antivir Ther; 2010; 15(6):803-16. PubMed ID: 20834093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
    Yazdanpanah Y; Fagard C; Descamps D; Taburet AM; Colin C; Roquebert B; Katlama C; Pialoux G; Jacomet C; Piketty C; Bollens D; Molina JM; Chêne G;
    Clin Infect Dis; 2009 Nov; 49(9):1441-9. PubMed ID: 19814627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.
    Königs C; Feiterna-Sperling C; Esposito S; Viscoli C; Rosso R; Kakuda TN; Leemans R; Peeters M; Mack R; Peeters I; Sinha R; Boven K; Giaquinto C
    AIDS; 2012 Feb; 26(4):447-55. PubMed ID: 22156961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
    Towner W; Lalezari J; Sension MG; Wohlfeiler M; Gathe J; Appelbaum JS; Bellman P; Gottlieb MS; Ryan R; Nijs S; Hoogstoel A; Van Solingen-Ristea R; Witek J
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):614-8. PubMed ID: 20134329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etravirine.
    Deeks ED; Keating GM
    Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.
    Pozniak AL; Morales-Ramirez J; Katabira E; Steyn D; Lupo SH; Santoscoy M; Grinsztejn B; Ruxrungtham K; Rimsky LT; Vanveggel S; Boven K;
    AIDS; 2010 Jan; 24(1):55-65. PubMed ID: 19926964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.
    Poveda E; de Mendoza C; Pattery T; González Mdel M; Villacian J; Soriano V
    AIDS; 2008 Nov; 22(17):2395-8. PubMed ID: 18981781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
    Kakuda TN; Wade JR; Snoeck E; Vis P; Schöller-Gyüre M; Peeters MP; Corbett C; Nijs S; Vingerhoets J; Leopold L; De Smedt G; Woodfall BJ; Hoetelmans RM
    Clin Pharmacol Ther; 2010 Nov; 88(5):695-703. PubMed ID: 20881958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Etravirine in highly treatment-experienced patients].
    Palter DP; Corbera EF; Tiraboschi JM
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simplification of antiretroviral therapy with etravirine.
    Martínez E; Nelson M
    AIDS Rev; 2010; 12(1):52-9. PubMed ID: 20216910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
    DeJesus E; Lalezari JP; Osiyemi OO; Ruane PJ; Ryan R; Kakuda TN; Witek J
    Antivir Ther; 2010; 15(5):711-20. PubMed ID: 20710052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US.
    Lyseng-Williamson KA
    Paediatr Drugs; 2012 Oct; 14(5):345-50. PubMed ID: 22897163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.